Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Non-Current Deffered Revenue (2022 - 2025)

Oramed Pharmaceuticals' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, changed N/A, while the annual FY2025 figure was $1.3 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $1.3 million in Q4 2025 per ORMP's latest filing, down from $2.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $4.0 million in Q3 2022 to a low of $1.3 million in Q4 2025.
  • Average Non-Current Deffered Revenue over 4 years is $3.2 million, with a median of $4.0 million recorded in 2022.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 100.0% in 2023, then crashed 56.9% in 2025.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then changed by 0.0% to $4.0 million in 2024, then crashed by 68.27% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Non-Current Deffered Revenue are $1.3 million (Q4 2025), $2.0 million (Q3 2025), and $1.7 million (Q2 2025).